
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
LUNAM | Vienna | EUR | Real-time | |
LUNB | Vienna | EUR | Real-time | |
0ND5 | London | DKK | Real-time | |
HLUNa | Copenhagen | DKK | Real-time | |
HLUNb | Copenhagen | DKK | Real-time |
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Hossein Armandi | 62 | 2022 | Employee Representative Director |
Santiago Arroyo | 64 | 2021 | Independent Director |
Jakob Riis | 58 | 2023 | Director |
Dorte Clausen | 40 | 2022 | Employee Representative Director |
Lasse Skibsbye | 41 | 2022 | Employee Representative Director |
Jeffrey Berkowitz | 58 | 2018 | Independent Director |
Camilla Gram Andersson | 52 | 2022 | Employee Representative Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review